Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06369974
PHASE1/PHASE2

Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with TUBB4A associated leukodystrophy.

Official title: An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy

Key Details

Gender

All

Age Range

4 Years - Any

Study Type

INTERVENTIONAL

Enrollment

1

Start Date

2024-09-18

Completion Date

2026-06

Last Updated

2026-03-02

Healthy Volunteers

No

Conditions

Interventions

DRUG

Antisense oligonucleotide treatment (ASO)

Drug: nL-TUBB4-001; Personalized antisense oligonucleotide

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States